Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TAK-881 by Takeda Pharmaceutical for Primary Immune Deficiency (PID): Likelihood of Approval
TAK-881 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Primary Immune Deficiency (PID). According to...
Zasocitinib by Takeda Pharmaceutical for Psoriatic Arthritis: Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase...
TAK-861 by Takeda Pharmaceutical for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....
Mobocertinib by Takeda Pharmaceutical for Metastatic Biliary Tract Cancer: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Fruquintinib by Takeda Pharmaceutical for Rectal Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Endometrial Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Lanadelumab by Takeda Pharmaceutical for Angioedema: Likelihood of Approval
Lanadelumab is under clinical development by Takeda Pharmaceutical and currently in Phase III for Angioedema. According to GlobalData, Phase III...
Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
C1 esterase inhibitor (human) by Takeda Pharmaceutical for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
C1 esterase inhibitor (human) is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acquired (Autoimmune) Hemolytic...
TAK-500 by Takeda Pharmaceutical for Pancreatic Cancer: Likelihood of Approval
TAK-500 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Mezagitamab by Takeda Pharmaceutical for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase I for IgA Nephropathy (Berger's Disease). According to...
Mezagitamab by Takeda Pharmaceutical for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Soticlestat by Takeda Pharmaceutical for Lennox-Gastaut Syndrome: Likelihood of Approval
Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase III for Lennox-Gastaut Syndrome. According to GlobalData, Phase...
Subasumstat by Takeda Pharmaceutical for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...
Subasumstat by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Subasumstat by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...